Evolus, Inc.

EOLS12 Dec 2024
Healthcare
$12.09
+0.01 (+0.66%)
Lowest Today
$11.99
Highest Today
$12.28
Today’s Open
$12.09
Prev. Close
$12.04
52 Week High
$17.82
52 Week Low
$9.65
To Invest in Evolus, Inc.

Evolus, Inc.

Healthcare
EOLS12 Dec 2024
+0.01 (+0.66%)
1M
3M
6M
1Y
5Y
Low
$11.98
Day’s Range
High
$12.28
11.98
52 Week Low
$9.65
52-Week Range
52 Week High
$17.82
9.65
1 Day
-
1 Week
-4.49%
1 month return
-2.57%
3 month return
-26.32%
6 month return
+5.2%
1 Year return
+23.23%
3 Years return
+110.05%
5 Years return
-2.33%
10 Years return
-
Institutional Holdings
Perceptive Advisors LLC
8.46
TANG CAPITAL MANAGEMENT LLC
7.66
BlackRock Inc
6.33
Vanguard Group Inc
5.05
Nantahala Capital Management, LLC
4.46
Great Point Partners LLC
3.87
Caligan Partners LP
3.46

Market Status

Fundamentals
Market Cap
762.39 mln
PB Ratio
130.94
PE Ratio
0
Enterprise Value
816.1 mln
Total Assets
189 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Organisation
Evolus, Inc.
Employees
322
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. David  Moatazedi
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities